TroyGould Advises Haitong International in its $190 Million Acquisition of Obagi Skincare Products Business

LOS ANGELES, Nov. 16, 2017

Limited partners in the Fund included an affiliate of China Regenerative Medicine International Limited, a Hong Kong Stock Exchange company principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products.

"This transaction marked the buyer group's inaugural acquisition in the US space, which we were delighted to facilitate," TroyGould Partner, David Ficksman, commented.

Dale Short, the Administrative Chair of TroyGould's Corporate Group added, "The acquisition highlighted TroyGould's results oriented approach and deep bench of experience in cross-border transactions, mergers and acquisitions, licensing and distribution arrangements, transition services, the biotech space and intellectual property matters.  We rolled up our sleeves and worked alongside our client to deliver an excellent result."

The TroyGould team was led by Partner David Ficksman and Chinese-speaking attorneys Dietrick Miller and Calvin Cheng, each of whom have deep experience handling complex, cross-border transactions.  Other attorneys on the TroyGould team included Sharon Gold, who advised on intellectual property matters, Martin Goldblum, who advised on tax matters, and Tony Shin and Christian Hollweg, who provided transactional advice.

About TroyGould

TroyGould is an innovative, mid-sized firm that uses creative and cost-effective means to help its clients achieve their goals.  The firm's clients range from start-ups to middle-market and Fortune 500 companies in a variety of industries, including life sciences, entertainment, real estate, technology, financial services, manufacturing, media, consumer products, health care and natural resources.  For more information, visit TroyGould.com.